

EXHIBIT C

TABLE OF CLAIM SUPPORT

Current Claims	IPER Claims	Additional Support in Specification and/or Additional Comments
38	1	Original claim 1; specification at pages 3-4, particularly at page 3, line 26 to page 4, line 16; Figure 1, particularly Figure 1D; "of the human CCR2 sequence" added to define the amino acid at position 64 and the presence or absence of the $\Delta 32$ deletion as pertaining to the human CCR2 sequence, as noted in IPER
--	2	Claim 2 from IPER canceled
39-41	3-5	Original claims 2-15
42	9	Original claim 23; "suitable container" supported in specification at page 7, line 11 and pages 26-27, including page 26, line 23
43 & 44	10 & 11	Original claim 24; specification at page 26, line 29 to page 30, line 7; specification at page 7, lines 26-29 and pages 15-20
45-47		Claims 3-5 from IPER adapted to refer to kits, as multiple-dependent EPO format is no longer used
48		A kit "further comprising at least a first anti-viral therapeutic agent" supported by claim 25 in original PCT application
49	12	Original claim 26
50	13	Reference to figure 1B now deleted, to match cancellation of claim 2 from IPER; support in original claim 21; specification at page 11, line 11 to page 13, line 9; Example 2 and Example 4
51-55	14-18	Original claims 21, 26 and 27; specification at page 11, line 11 to page 13, line 9; Example 2 and Example 4
--	19	Claim 19 from IPER canceled as precaution in case interpreted as multiple dependent claim
56-58	20-22	Original claims 28-32
59		Dependent claim based upon claim 23 from IPER; support in original claims 33 to 37
60	23	Independent claim based upon claim 23 from IPER, also supported by claim 34 in original PCT application, presented in (a) and (b) format
61 & 62	6 & 7	Original claim 6; Figure 1D
--	8	Claim 8 from IPER canceled for economic reasons

EXHIBIT D
REPLACEMENT PARAGRAPHS

At page 1, lines 7-11 of the specification, the deletions and additions are as shown:

The present application is a nationalization of PCT Application Serial No. PCT/US00/28158, filed October 12, 2000, which claims priority to U.S. provisional application Serial No. 60/159,137, filed October 12, 1999, the entire text, figures and sequences of which [application] applications are incorporated herein by reference without disclaimer. The U.S. government owns rights in the present invention pursuant to grant numbers AI43279 and AI46326 from the National Institutes of Health.

At page 1, lines 7-11 of the specification, the final text is as follows:

The present application is a nationalization of PCT Application Serial No. PCT/US00/28158, filed October 12, 2000, which claims priority to U.S. provisional application Serial No. 60/159,137, filed October 12, 1999, the entire text, figures and sequences of which applications are incorporated herein by reference without disclaimer. The U.S. government owns rights in the present invention pursuant to grant numbers AI43279 and AI46326 from the National Institutes of Health.